within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B02A_Antifibrinolytics.B02AA02_TranexamicAcid;

model TranexamicAcid
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 1.833333333333333e-06,
    adminDuration = 600,
    adminMass = 1000 / 1000000,
    adminCount = 1,
    Vd = 0.009,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>TranexamicAcid</td></tr><tr><td>ATC code:</td><td>B02AA02</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>1000</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>9</td><td>L</td></tr>
    <tr><td>clearance:</td><td>110</td><td>mL/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Tranexamic acid is an antifibrinolytic agent that inhibits plasminogen activation, thereby preventing fibrinolysis and stabilizing blood clots. It is primarily used to treat or prevent excessive bleeding in various medical conditions, including during surgery, trauma, heavy menstrual bleeding (menorrhagia), and in certain bleeding disorders. Tranexamic acid is approved for use in many countries worldwide.</p><h4>Pharmacokinetics</h4><p>Single-dose intravenous administration in healthy adult volunteers.</p><h4>References</h4><ol><li><p>González Osuna, A, et al., &amp; Valle, M (2022). Population Pharmacokinetics of Intra-articular and Intravenous Administration of Tranexamic Acid in Patients Undergoing Total Knee Replacement. <i>Clinical pharmacokinetics</i> 61(1) 83–95. DOI:<a href=\"https://doi.org/10.1007/s40262-021-01043-9\">10.1007/s40262-021-01043-9</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34255299/\">https://pubmed.ncbi.nlm.nih.gov/34255299</a></p></li><li><p>Li, S, et al., &amp; Gobburu, JVS (2021). Population pharmacokinetics and pharmacodynamics of Tranexamic acid in women undergoing caesarean delivery. <i>British journal of clinical pharmacology</i> 87(9) 3531–3541. DOI:<a href=\"https://doi.org/10.1111/bcp.14767\">10.1111/bcp.14767</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33576009/\">https://pubmed.ncbi.nlm.nih.gov/33576009</a></p></li><li><p>Grassin-Delyle, S, et al., &amp; Shakur-Still, H (2022). Pharmacokinetics of tranexamic acid after intravenous, intramuscular, and oral routes: a prospective, randomised, crossover trial in healthy volunteers. <i>British journal of anaesthesia</i> 128(3) 465–472. DOI:<a href=\"https://doi.org/10.1016/j.bja.2021.10.054\">10.1016/j.bja.2021.10.054</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34998508/\">https://pubmed.ncbi.nlm.nih.gov/34998508</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.B.B02AA02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end TranexamicAcid;
